Johnson & Johnson
NYSE:JNJ

Watchlist Manager
Johnson & Johnson Logo
Johnson & Johnson
NYSE:JNJ
Watchlist
Price: 162.74 USD -0.92%
Market Cap: 391.8B USD
Have any thoughts about
Johnson & Johnson?
Write Note
Section:
 

Relative Value

The Relative Value of one JNJ stock under the Base Case scenario is 178 USD. Compared to the current market price of 162.74 USD, Johnson & Johnson is Undervalued by 9%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

JNJ Relative Value
Base Case
178 USD
Undervaluation 9%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

4.4
P/S
P/S
Price to Sales
4.4
vs History
52
vs Industry
30
Median 3Y
4.7
Median 5Y
4.5
Industry
2.4
Forward
4.3
More Details
27.8
P/E
P/E
Price to Earnings
27.8
vs History
9
vs Industry
37
Median 3Y
22.1
Median 5Y
22.1
Industry
20.2
Forward
15.2
More Details
16.2
P/OCF
P/OCF
Price to OCF
16.2
vs History
47
vs Industry
26
Median 3Y
17.2
Median 5Y
16.3
Industry
15.1
More Details
14.2
P/FCFE
P/FCFE
Price to FCFE
14.2
vs History
73
vs Industry
11
Median 3Y
17.3
Median 5Y
16.7
Industry
22.3
More Details
5.5
P/B
P/B
Price to Book Value
5.5
vs History
47
vs Industry
14
Median 3Y
5.4
Median 5Y
5.5
Industry
2
More Details
4.5
EV/S
EV/S
Enterprise Value to Sales
4.5
vs History
50
vs Industry
27
Median 3Y
4.9
Median 5Y
4.6
Industry
2.5
Forward
4.4
More Details
6.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
6.6
vs History
52
vs Industry
33
Median 3Y
7.1
Median 5Y
6.7
Industry
4.9
More Details
13
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
13
vs History
55
vs Industry
31
Median 3Y
13.2
Median 5Y
13.4
Industry
12.3
Forward
11.9
More Details
17.1
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
17.1
vs History
53
vs Industry
28
Median 3Y
17.1
Median 5Y
17.6
Industry
15.3
Forward
13.5
More Details
16.5
EV/OCF
EV/OCF
Enterprise Value to OCF
16.5
vs History
42
vs Industry
26
Median 3Y
17.2
Median 5Y
16.6
Industry
13.6
More Details
20.2
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
20.2
vs History
38
vs Industry
20
Median 3Y
21.2
Median 5Y
20.1
Industry
17.5
More Details
2.8
EV/IC
EV/IC
Enterprise Value to IC
2.8
vs History
39
vs Industry
28
Median 3Y
2.8
Median 5Y
2.7
Industry
1.7
More Details

Multiples Across Competitors

JNJ Competitors Multiples
Johnson & Johnson Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Johnson & Johnson
NYSE:JNJ
391B USD 4.4 27.8 13 17.1
US
Eli Lilly and Co
NYSE:LLY
788.6B USD 17.5 74.5 43.3 47.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.4T DKK 8.4 24 15.8 17.9
CH
Roche Holding AG
SIX:ROG
244.2B CHF 4.2 21.2 11.8 14
UK
AstraZeneca PLC
LSE:AZN
182.7B GBP 4.4 33.8 127.4 194.5
US
Merck & Co Inc
NYSE:MRK
237.4B USD 3.7 13.9 9.3 11
CH
Novartis AG
SIX:NOVN
199.4B CHF 4.4 19 11.5 14.7
IE
Endo International PLC
LSE:0Y5F
166.1B USD 71.6 -56.8 265.3 665.3
US
Pfizer Inc
NYSE:PFE
148.2B USD 2.3 18.4 8.8 12.5
FR
Sanofi SA
PAR:SAN
134.7B EUR 3 23.5 10.2 14.9
P/E Multiple
Earnings Growth PEG
US
Johnson & Johnson
NYSE:JNJ
Average P/E: 28.5
27.8
26%
1.1
US
Eli Lilly and Co
NYSE:LLY
74.5
48%
1.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
24
19%
1.3
CH
Roche Holding AG
SIX:ROG
21.2
16%
1.3
UK
AstraZeneca PLC
LSE:AZN
33.8
36%
0.9
US
Merck & Co Inc
NYSE:MRK
13.9
17%
0.8
CH
Novartis AG
SIX:NOVN
19
16%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56.8 N/A N/A
US
Pfizer Inc
NYSE:PFE
18.4
29%
0.6
FR
Sanofi SA
PAR:SAN
23.5
29%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Johnson & Johnson
NYSE:JNJ
Average EV/EBITDA: 396.6
13
7%
1.9
US
Eli Lilly and Co
NYSE:LLY
43.3
29%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
DK
Novo Nordisk A/S
CSE:NOVO B
15.8
11%
1.4
CH
Roche Holding AG
SIX:ROG
11.8
7%
1.7
UK
AstraZeneca PLC
LSE:AZN
127.4
8%
15.9
US
Merck & Co Inc
NYSE:MRK
9.3
11%
0.8
CH
Novartis AG
SIX:NOVN
11.5
4%
2.9
IE
E
Endo International PLC
LSE:0Y5F
265.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
8.8
2%
4.4
FR
Sanofi SA
PAR:SAN
10.2
7%
1.5
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Johnson & Johnson
NYSE:JNJ
Average EV/EBIT: 1 701.1
17.1
11%
1.6
US
Eli Lilly and Co
NYSE:LLY
47.8
31%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
DK
Novo Nordisk A/S
CSE:NOVO B
17.9
16%
1.1
CH
Roche Holding AG
SIX:ROG
14
9%
1.6
UK
AstraZeneca PLC
LSE:AZN
194.5
19%
10.2
US
Merck & Co Inc
NYSE:MRK
11
12%
0.9
CH
Novartis AG
SIX:NOVN
14.7
9%
1.6
IE
E
Endo International PLC
LSE:0Y5F
665.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
12.5
10%
1.2
FR
Sanofi SA
PAR:SAN
14.9
14%
1.1

See Also

Summary
JNJ intrinsic value, competitors valuation, and company profile.
DCF Valuation
JNJ stock valuation using Discount Cash Flow valuation method.
Relative Valuation
JNJ stock valuation using valuation multiples.
Wall Street Estimates
JNJ price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
JNJ stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 239,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.